You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is the current cost of COPD therapies?

30-day Acquisition Cost based on List Price: Maintenance Therapies for the Treatment of
COPD
[1].

Please note: All formoterol preparations are assumed to be dosed at 12mcg twice a day. This information is sensitive to price changes; drug costs and information for currently available COPD therapies were last updated in May 2017[1]. Prescribing decisions should not be based on cost alone. You should refer to the SPC of each medicine for further information such as indications, contraindications, precautions and adverse events.

For appropriate COPD patients:

See how Relvar can impact your budget

Cost Calculator

Incruse and Relvar Ellipta devices

See how Relvar and Incruse can impact your budget

Cost Calculator

What potential cost savings could the Ellipta portfolio offer in your locality?

To discuss potential cost savings available in your locality please contact us via the ‘HOC: on-Demand’ service available through this webpage.

Download the 30 day drug acquisition cost information for COPD medications

References:

  1. Monthly Index of Medical Specialities Online. Available at: http://www.mims.co.uk/ [Accessed May 2017]

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Anoro, Incruse, Ellipta, Seretide, Accuhaler and Evohaler are registered trademarks of the GlaxoSmithKline group of companies